CN106831974A - 一种胜肽及其应用 - Google Patents
一种胜肽及其应用 Download PDFInfo
- Publication number
- CN106831974A CN106831974A CN201610840982.4A CN201610840982A CN106831974A CN 106831974 A CN106831974 A CN 106831974A CN 201610840982 A CN201610840982 A CN 201610840982A CN 106831974 A CN106831974 A CN 106831974A
- Authority
- CN
- China
- Prior art keywords
- prepared
- application
- hair
- victory peptide
- accelerator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 37
- 230000002500 effect on skin Effects 0.000 claims abstract description 20
- 230000003779 hair growth Effects 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 230000009583 hair follicle growth Effects 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims description 13
- 210000003780 hair follicle Anatomy 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 210000004209 hair Anatomy 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007962 solid dispersion Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims 3
- 235000013361 beverage Nutrition 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- -1 finish Substances 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 239000007887 hard shell capsule Substances 0.000 claims 1
- 238000000465 moulding Methods 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 abstract description 6
- 239000007952 growth promoter Substances 0.000 abstract description 3
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 23
- 230000035755 proliferation Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 3
- 229960002256 spironolactone Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000623905 Homo sapiens Mucin-15 Proteins 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 101710155097 Mucin-15 Proteins 0.000 description 1
- 102100023128 Mucin-15 Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000055688 human MUC15 Human genes 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 210000004918 root sheath Anatomy 0.000 description 1
- 230000035936 sexual power Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提出一种胜肽，由SEQ ID NO：1所示的胺基酸序列所组成。此外，本发明还提出所提的胜肽用于制备真皮乳突细胞增生的促进剂、用于制备毛囊生长促进剂与用于制备毛发生长剂等用途。
Description
技术领域
本发明关于一种胜肽，且特别关于一种用于促进毛发生长的胜肽。
背景技术
敏洛西迪(minoxidil)、螺内酯(spironolactone)及非那雄安(finasteride)是目前常见的毛发生长成分。敏洛西迪与螺内酯可制作成外用涂剂来改善秃头，非那雄安则可制作成口服用药来改善秃头。然而，这些化合物非来自天然，须通过化学合成始能取得，因此施用于生物体时，可能会对其造成副作用。举例而言，敏洛西迪常见的副作用如对眼睛产生灼热或刺痛感、对施予部位造成红肿、搔痒或刺激，螺内酯常见的副作用如电解质失衡(以高血钠症为常见)、恶心、呕吐、头痛、疹子或性欲降低，而非那雄安常见的副作用如性能力降低。
发明内容
本发明的目的在于提供一种胜肽及其应用。
为实现上述目的，本发明提供一种胜肽，其由SEQ ID NO：1所示的胺基酸序列所组成。
在一实施方式中，该胜肽可通过从生物体萃取并经消化处理取得、化学合成取得或基因工程取得。
为实现上述目的，本发明还提供一种前述胜肽在制备真皮乳突细胞增生促进剂中的应用。
在一实施方式中，真皮乳突细胞增生促进剂可制备成液体(如细胞培养液)、块体或粉体形式。
为实现上述目的，本发明还提供一种前述胜肽在制备毛囊生长促进剂中的应用。
在一实施方式中，毛囊生长促进剂可制备成液体(如毛囊组织培养液)、块体或粉体形式。
本发明还提供一种前述胜肽在制备毛发生长剂中的应用。
在一实施方式中，毛发生长剂可制备成化妆料、外用制剂、内服制剂、食品或饮品形式。
在另一实施方式中，化妆料可为洗发精、润发精、发型造型品、睫毛膏或宠物用沐浴乳。
在又一实施方式中，外用制剂可呈洗剂、乳膏剂、凝胶、油剂、软膏剂、油膏剂、乳液、溶液或悬浮液形式。
在再一实施方式中，内服制剂可呈硬胶囊、软胶囊、锭剂、糖浆、悬浮液、乳液、溶液、固态分散体、粉片或酏剂形式。
本发明是基于一项不可预料的发现所完成的。在此，找到人类黏蛋白-15(Mucin-15)中的一特定胺基酸片段会促进大鼠真皮乳突细胞(dermal papilla cell)增生。此外，依文献Cold Spring Harb Perspect Med.2014 Jul 1；4(7)所述，真皮乳突细胞的增生可促进毛囊生长，进而导致毛发生长。故，可合理地理解到所找到的氨基酸片段也可促进毛囊与毛发的生长。
本发明的有益效果是：本发明所提供的胜肽可促进真皮乳突细胞增生并可进一步地应用于促进毛囊生长与毛发生长等相关用途。此外，本发明所提供的胜肽来自于天然，因而具有高生物兼容性，以降低施用于生物体时所产生的副作用。
附图说明
图1为本发明不同物质处理真皮乳突细胞48及96小时后的细胞增生情况的直方图。
具体实施方式
为让本发明上述及/或其他目的、功效、特征更明显易懂，下文特举具体实施例，作详细说明于下：
《实例1：胜肽的制备》
Mucinhair胜肽(序列为：NTSDPQKENRNTG)委托生工有限公司(MDBio,Inc)合成，且通过型号为Applied Biosystems 433A Peptide Synthesis System的合成仪来合成。此外，合成原理为本发明所属技术领域人士所熟悉的，可参考Albericio,F.Solid-PhaseSynthesis:A Practical Guide 1.Boca Raton:CRC Press.2000:848.ISBN 0-8247-0359-6。Mucinhair胜肽合成后通过高效液相层析仪(high performance liquidchromatography，HPLC)与质谱仪(mass spectrometer，MS)分析确认序列与纯度。接着，将Mucinhair胜肽溶解于去离子蒸馏水中，以取得浓度为12.84μM的Mucinhair胜肽溶液。
《实例2：真皮乳突细胞的分离》
取下六周大的大鼠(购自乐斯科生物科技股份有限公司)两颊胡须的毛囊。将所取的毛囊的根部剪下并置于第1型胶原蛋白酶溶液(浓度为2mg/mL，含1％胎牛血清(fetalbovine serum，FBS)的杜氏改良式伊格培养液(Dulbecco's Modified Eagle Medium，DMEM))中。接着，将此溶液置于温度37℃且二氧化碳浓度5％的培养箱中约2小时。在外根鞘松动后，加入含10％FBS的DMEM培养液至上述溶液中，并在所得的混合液轻微搅拌后，离心以分离出真皮乳突细胞。然后，在保留真皮乳突细胞后，重新添加含20％FBS的DMEM培养液至细胞进行培养。在观察到细胞贴附于培养皿底部并有向外延伸状态后，每隔3天替换一次培养液，并于培养后第7天进行后续实验。
《实例3：细胞增生的分析》
本实例采用MTT(3-(4,5-二甲基-2-噻唑)-2,5-二苯基溴化四唑，3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)方法。MTT方法的原理与详细操作为本发明所属技术领域的普通技术人员所熟悉的，于此不再赘述。须提出的是：分析前，以每孔1,000个细胞密度将真皮乳突细胞种在含有20％FBS的DMEM培养液的96孔盘内。另须提出的是：细胞贴附后，添加等体积的去离子蒸馏水(在后文，称作“控制组”)或12.84μM的Mucinhair胜肽溶液至细胞，并再次培养细胞。又须提出的是：下文所述的“细胞增生相对比值”指某一物质处理细胞特定时间后利用MTT方法测得的数值除以同一物质处理细胞0小时后利用MTT方法测得的数值所得到的商。
细胞增生分析结果请参照图1。由此可知，处理48小时后，控制组处理后的真皮乳突细胞的增生相对比值为1.77±0.12，Mucinhair胜肽溶液处理后的真皮乳突细胞的增生相对比值为2.26±0.23；而处理96小时后，控制组处理后的真皮乳突细胞的增生相对比值为2.68±0.20，Mucinhair胜肽溶液处理后的真皮乳突细胞的增生相对比值为3.31±0.21。上述结果说明着：相对于控制组，Mucinhair胜肽确实可促进真皮乳突细胞生长。
综上，证实着本发明所提的胜肽可促进真皮乳突细胞增生。如此一来，此胜肽可进一步地应用于促进毛囊生长与毛发生长等相关用途。此外，本发明所提的胜肽来自于天然，因而具有高生物兼容性，以降低施用于生物体时所产生的副作用。
当然，本发明还可有其它多种实施例，在不背离本发明精神及其实质的情况下，熟悉本领域的技术人员可根据本发明作出各种相应的改变和变形，但这些相应的改变和变形都应属于本发明权利要求的保护范围。
Claims (11)
1.一种胜肽，其特征在于，由SEQ ID NO：1所示的胺基酸序列所组成。
2.根据权利要求1所述的胜肽，其特征在于，该胜肽通过从生物体萃取并经消化处理取得、化学合成取得或基因工程取得。
3.权利要求1所述的胜肽在制备真皮乳突细胞增生促进剂中的应用。
4.根据权利要求3所述的胜肽在制备真皮乳突细胞增生促进剂中的应用，其特征在于，该真皮乳突细胞增生促进剂制备成液体、块体或粉体形式。
5.权利要求1所述的胜肽在制备毛囊生长促进剂中的应用。
6.根据权利要求5所述的胜肽在制备毛囊生长促进剂中的应用，其特征在于，该毛囊生长促进剂制备成液体、块体或粉体形式。
7.权利要求1所述的胜肽在制备毛发生长剂中的应用。
8.根据权利要求7所述的胜肽在制备毛发生长剂中的应用，其特征在于，该毛发生长剂制备成化妆料、外用制剂、内服制剂、食品或饮品形式。
9.根据权利要求8所述的胜肽在制备毛发生长剂中的应用，其特征在于，该化妆料是洗发精、润发精、发型造型品、睫毛膏或宠物用沐浴乳。
10.根据权利要求8所述的胜肽在制备毛发生长剂中的应用，其特征在于，该外用制剂呈洗剂、乳膏剂、凝胶、油剂、软膏剂、油膏剂、乳液、溶液或悬浮液形式。
11.根据权利要求8所述的胜肽在制备毛发生长剂中的应用，其特征在于，该内服制剂呈硬胶囊、软胶囊、锭剂、糖浆、悬浮液、乳液、溶液、固态分散体、粉片或酏剂形式。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610840982.4A CN106831974B (zh) | 2016-09-22 | 2016-09-22 | 一种胜肽及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610840982.4A CN106831974B (zh) | 2016-09-22 | 2016-09-22 | 一种胜肽及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106831974A true CN106831974A (zh) | 2017-06-13 |
| CN106831974B CN106831974B (zh) | 2020-08-18 |
Family
ID=59145581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610840982.4A Active CN106831974B (zh) | 2016-09-22 | 2016-09-22 | 一种胜肽及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106831974B (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1445236A (zh) * | 2001-11-13 | 2003-10-01 | 住友电气工业株式会社 | 促进毛发生长的寡肽 |
| WO2007109223A2 (en) * | 2006-03-17 | 2007-09-27 | Intercytex Limited | Cell co-culture for hair follicle production |
| CN104903345A (zh) * | 2012-09-17 | 2015-09-09 | 财团法人台湾基督长老教会马偕纪念社会事业基金会马偕纪念医院 | Pedf衍生的多肽在治疗脱发和/或毛发脱色中的用途 |
| CN105106028A (zh) * | 2015-08-28 | 2015-12-02 | 深圳市维琪医药研发有限公司 | 一种用于毛发生长的多肽组合物 |
-
2016
- 2016-09-22 CN CN201610840982.4A patent/CN106831974B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1445236A (zh) * | 2001-11-13 | 2003-10-01 | 住友电气工业株式会社 | 促进毛发生长的寡肽 |
| WO2007109223A2 (en) * | 2006-03-17 | 2007-09-27 | Intercytex Limited | Cell co-culture for hair follicle production |
| CN104903345A (zh) * | 2012-09-17 | 2015-09-09 | 财团法人台湾基督长老教会马偕纪念社会事业基金会马偕纪念医院 | Pedf衍生的多肽在治疗脱发和/或毛发脱色中的用途 |
| CN105106028A (zh) * | 2015-08-28 | 2015-12-02 | 深圳市维琪医药研发有限公司 | 一种用于毛发生长的多肽组合物 |
Non-Patent Citations (3)
| Title |
|---|
| AMANDA J. REYNOLDS等: "Inductive Properties of Hair Follicle Cells", 《ANNALS NEW YORK ACADEMY OF SCIENCES》 * |
| LINDA V. GOODMAN等: "Secretion of Stromelysin by Cultured Dermal Papilla Cells: Differential Regulation by Growth Factors and Functional Role in Mitogen-Induced Cell Proliferation", 《JOURNAL OF CELLULAR PHYSIOLOGY》 * |
| 邓小英等: "矿物肽治疗脱发及白发患者的创新性应用研究", 《日用化妆品科学》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106831974B (zh) | 2020-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105218661B (zh) | Wnt系列衍生肽及其用途 | |
| JP2006117700A (ja) | 抗グリケーション剤としての少なくとも１つのスノキ属植物の抽出物の使用 | |
| US10702544B2 (en) | Composition for ameliorating loss of hair and graying of hair, and use thereof | |
| KR101938548B1 (ko) | 마이크로 ｒｎａ를 포함하는 색소형성유전자 발현조절용 조성물 | |
| KR101187871B1 (ko) | Ｆｇｆ１０－유래 펩타이드 및 그의 용도 | |
| CN111759748B (zh) | 一种抗衰老肽类组合物及其应用 | |
| CN114828872B (zh) | 育毛剂 | |
| CN110092815B (zh) | 具有抗炎症、骨形成及生发促进活性的肽及其的用途 | |
| KR101160926B1 (ko) | 탈모방지 및 모발생장 촉진용 생약재 추출물의 정제방법 및 이를 이용한 화장료 조성물 | |
| CN103764675B (zh) | 外异蛋白a受体配体衍生肽及其用途 | |
| US11608490B2 (en) | Composition for enhancing hair growth-inducing ability of adipose stem cells comprising udenafil as active ingredient | |
| KR20120122874A (ko) | 탈모방지 및 모발생장 촉진용 생약재 추출물의 정제방법 및 이를 이용한 화장료 조성물 | |
| CN106831974B (zh) | 一种胜肽及其应用 | |
| KR101902425B1 (ko) | 치자 추출물을 포함하는 재생 촉진제 | |
| EP3360894A1 (en) | Functional regulatory antibody having actions of promoting proliferation, survival, and cell activation of dermal papilla cells as hair growth regulating center cells and use thereof | |
| TWI585108B (zh) | 用於促進毛髮生長的胜肽 | |
| KR101871920B1 (ko) | 마이크로 ｒｎａ를 포함하는 조성물 | |
| US20130216632A1 (en) | Method for Controlling Hair Growth, Method for Selecting or Evaluating Hair Growth Control Agent, and Hair Growth Suppression Agent | |
| CN103936608A (zh) | 一种新型查尔酮化合物的抗衰老活性 | |
| CN117802010B (zh) | 发酵乳杆菌发酵滤液、其制备方法及其应用 | |
| CN111909960B (zh) | 一种肽和/或蛋白质组合物使用比例的筛选方法 | |
| JP6892903B2 (ja) | メラニンの生成を促進するペプチドおよびその方法 | |
| CN117794509A (zh) | 育毛剂 | |
| US20230241031A1 (en) | Composition, Comprising Rip Kinase Inhibitor, For Preventing Hair Loss Or Promoting Hair Regrowth | |
| JP2024063294A (ja) | 髪のうねり予防又は改善剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |